International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences’ hepatitis C drug Sofosbuvir at the European Patent Office in order to increase access to the treatment.

A potentially live-saving liver cancer drug that costs €560 per tablet will be made available to more than 100 seriously ill patients six months after doctors treating the disease asked the Government to fund it.